Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Chairman Stanley T. Crooke sold 27,500 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $52.89, for a total transaction of $1,454,475.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Ionis Pharmaceuticals, Inc. (NASDAQ IONS) opened at 55.55 on Friday. The company has a market capitalization of $6.91 billion, a P/E ratio of 267.07 and a beta of 3.12. Ionis Pharmaceuticals, Inc. has a 52 week low of $24.58 and a 52 week high of $60.01. The firm has a 50 day moving average of $53.28 and a 200-day moving average of $48.97.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Tuesday, August 8th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The company had revenue of $104.15 million during the quarter, compared to the consensus estimate of $93.29 million. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The firm’s revenue was up 170.7% compared to the same quarter last year. During the same period last year, the company posted ($0.47) EPS. On average, analysts forecast that Ionis Pharmaceuticals, Inc. will post ($0.17) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Insider Selling: Ionis Pharmaceuticals, Inc. (IONS) Chairman Sells $1,454,475.00 in Stock” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/insider-selling-ionis-pharmaceuticals-inc-ions-chairman-sells-1454475-00-in-stock/1614468.html.

Several equities analysts recently issued reports on the stock. Goldman Sachs Group, Inc. (The) reissued a “sell” rating and set a $30.00 price target on shares of Ionis Pharmaceuticals in a report on Friday. BMO Capital Markets reissued an “outperform” rating and set a $69.00 price target on shares of Ionis Pharmaceuticals in a report on Monday, October 2nd. Jefferies Group LLC reissued an “underperform” rating and set a $18.00 price target (up from $17.00) on shares of Ionis Pharmaceuticals in a report on Thursday, August 10th. Laidlaw reissued a “buy” rating and set a $65.00 price target on shares of Ionis Pharmaceuticals in a report on Monday, August 14th. Finally, Sanford C. Bernstein assumed coverage on shares of Ionis Pharmaceuticals in a report on Thursday, July 27th. They set a “market perform” rating and a $57.00 price target for the company. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company. Ionis Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $49.44.

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. raised its holdings in Ionis Pharmaceuticals by 37,569.7% in the 1st quarter. BlackRock Inc. now owns 6,559,808 shares of the company’s stock valued at $263,704,000 after buying an additional 6,542,394 shares during the last quarter. State Street Corp raised its holdings in Ionis Pharmaceuticals by 20.5% in the 1st quarter. State Street Corp now owns 3,340,471 shares of the company’s stock valued at $134,285,000 after buying an additional 567,792 shares during the last quarter. Vanguard Group Inc. raised its holdings in Ionis Pharmaceuticals by 4.4% in the 2nd quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock valued at $501,332,000 after buying an additional 417,364 shares during the last quarter. Smith Asset Management Group LP bought a new position in Ionis Pharmaceuticals in the 2nd quarter valued at approximately $11,394,000. Finally, Gotham Asset Management LLC raised its holdings in Ionis Pharmaceuticals by 227.6% in the 1st quarter. Gotham Asset Management LLC now owns 313,432 shares of the company’s stock valued at $12,600,000 after buying an additional 217,756 shares during the last quarter. 89.24% of the stock is owned by hedge funds and other institutional investors.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.